LLY - Eli Lilly and Co
501
$906.70
-$10.80 (-1.177%)
$911.48
$4.78 (0.527%)
Score4.55/5
Price Targets
73.7%
35.3%
-7.5%
Most Recent Recommendations
Revenue Estimate
- Past Revenue
- Avg
- High
- Low
EPS Estimate
- Past EPS
- Avg
- High
- Low
Revenue Estimate as % change
| 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | |
|---|---|---|---|---|---|---|---|---|
| Low | 26.2% | 11.2% | 9.09% | 8.71% | 3.73% | 6.86% | 3.97% | 0.83% |
| Avg | 28.4% | 16.3% | 13.2% | 9.81% | 8.20% | 6.57% | 5.71% | 4.68% |
| High | 36.0% | 17.3% | 16.1% | 14.0% | 9.89% | 0.97% | 8.47% | 9.27% |
EPS Estimate as % change
| 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | |
|---|---|---|---|---|---|---|---|---|
| Low | 45.9% | 15.2% | 13.5% | 13.3% | 6.72% | 10.7% | 8.98% | 0.46% |
| Avg | 47.7% | 22.2% | 17.6% | 11.0% | 10.4% | 8.76% | 7.41% | 5.84% |
| High | 58.7% | 22.3% | 22.6% | 11.9% | 11.7% | 8.06% | 8.30% | 14.2% |
Recommendation Trends
- Strong Sells
- Sells
- Holds
- Buys
- Strong Buys
Latest Analyst Ratings
Institution | Action | Grade | Old Grade | Date |
|---|---|---|---|---|
| HSBC | Downgrade | Reduce | Hold | 2026-03-17 |
| RBC Capital | Init | Outperform | -- | 2026-02-25 |
| Barclays | Init | Overweight | -- | 2026-02-20 |
| Deutsche Bank | Maintain | Buy | Buy | 2026-02-09 |
| Cantor Fitzgerald | Maintain | Overweight | Overweight | 2026-02-05 |
| JP Morgan | Maintain | Overweight | Overweight | 2026-02-05 |
| Wells Fargo | Maintain | Overweight | Overweight | 2026-02-05 |
| Morgan Stanley | Maintain | Overweight | Overweight | 2026-02-05 |
| Guggenheim | Maintain | Buy | Buy | 2026-01-20 |
| B of A Securities | Maintain | Buy | Buy | 2025-12-15 |